BOTHELL, Wash., June 02, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of migraine, and preclinical data from a case study of ALD403 and other CGRP-antibodies will be presented at the upcoming 58th Annual Scientific Meeting of the American Headache Society on June 9-12, 2016 in San Diego.
- Oral presentation by Jeffrey T.L. Smith, M.D., FRCP, Senior Vice President, Translational Medicine at Alder: “Randomized, Double-Blind, Placebo-Controlled Trial of ALD403, an Anti-CGRP Peptide Antibody in the Prevention of Chronic Migraine”
Oral Session: Scientific Paper Presentations - Session 2
Presenter: Dr. Jeffrey Smith
Date: Saturday, June 11
Time: 11 am PDT
Location: Marina Ballroom, D-F
- Poster presentation: “A Characterization of the CGRP-Antibody Interactions of Therapeutic Antibodies Effective in Preventing Migraine: a Comparative Pre-Clinical Case Study of ALD403 and Other CGRP Antibodies”
Poster #: PS74LB
Date: Friday, June 10
Poster Q & A Session: 1:15 pm – 2:30 pm PDT
Location: San Diego Ballroom
- Poster presentation: “A Multiple Dose, Placebo-Controlled, Randomized Phase I Clinical Trial of ALD403, a Humanized anti-Calcitonin Gene-Related Peptide Monoclonal Antibody, Administered Once Every 3-Months via IV, SC, or IM – Pharmacokinetic and Pharmacodynamic Results”
Poster #: PS79LB
Date: Saturday, June 11
Poster Q & A Session: 12:30 pm – 2:00 pm PDT
Location: San Diego Ballroom
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. ALD403, Alder's lead pivotal-stage product candidate being evaluated for migraine prevention, is a genetically engineered monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). CGRP is a small protein with a well-established role in the initiation, transmission and heightened sensitivity to migraine pain. Alder's second program, ALD1613, targets adrenocorticotropic hormone (ACTH) and is intended for the treatment of congenital adrenal hyperplasia and Cushing's disease. ALD1613 is undergoing Investigational New Drug (IND)-enabling preclinical studies, and an IND submission is planned for 2016. Additionally, clazakizumab, a monoclonal antibody therapeutic candidate discovered by Alder designed to block interleukin-6, is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements relating to: the continued development and clinical, therapeutic and commercial potential of ALD403 and ALD1613; and future regulatory filings. Words such as "potential," "intended," "planned," or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Alder's current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: risks related to the potential failure of ALD403 and ALD1613 to demonstrate safety and efficacy in clinical testing; the availability of data at the expected times; the clinical, therapeutic and commercial value of ALD403 and ALD1613; risks and uncertainties related to regulatory review and approval processes and Alder's compliance with applicable legal and regulatory requirements; and other factors discussed under the caption "Risk Factors" in Alder's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016, which was filed with the Securities and Exchange Commission (SEC) on April 28, 2016, and is available on the SEC's website at www.sec.gov. Additional information will also be set forth in Alder's other reports and filings it will make with the SEC from time to time. The forward-looking statements made in this press release speak only as of the date of this press release. Alder expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Alder's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.